Abstract
No public abstract is available from the verified source records.
Seunghee Na, Hyun Sook Kim, Geon Ha Kim, Oh Dae Kwon, Yong Soo Shim, Chan-Nyoung Lee, Hak Young Rhee, Hojin Choi, Yun Jeong Hong, So Young Moon, Kee Hyung Park
Abstract
Authors
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019
10.1016/s2468-2667(21)00249-8 · 2022
Prevalence and incidence of dementia in South Korea: a nationwide analysis of the National Health Insurance Service Senior Cohort
10.3988/jcn.2021.17.2.249 · 2021
Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial
10.1001/jama.2023.13239 · 2023
Lecanemab in early Alzheimer’s disease
10.1056/nejmoa2212948 · 2023
Eligibility for lecanemab treatment in the Republic of Korea: real-world data from memory clinics
10.3988/jcn.2024.0550 · 2025
Eligibility for lecanemab and donanemab in Korea under Appropriate Use Recommendations
10.1002/alz.70875 · 2025
The effects of memantine on behavioral disturbances in patients with Alzheimer’s disease: a meta-analysis
10.2147/ndt.s142839 · 2017
Memantine for dementia
2019
Memantine in moderate-to-severe Alzheimer’s disease
10.1056/nejmoa013128 · 2003
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
unpaywall
Confidence 95%
datacite
Confidence 0%
Dynamic associations of cholinesterase inhibitors and memantine with cognitive trajectories in individuals with Alzheimer’s or mixed dementia: a real-world analysis using the quality registry SveDem
10.1186/s13195-025-01918-0 · 2025
Memantine therapy for Alzheimer disease in real-world practice: an observational study in a large representative sample of French patients
10.1097/wad.0b013e31815a9e10 · 2008
A multicentre, randomised, open-label, prospective study to estimate the add-on effects of memantine as Ebixa® oral pump (solution) on language in patients with moderate to severe Alzheimer’s disease already receiving donepezil (ROMEO-AD)
10.1007/s40120-023-00494-5 · 2023
Unresolved referenced work
1992
Prognosis of Alzheimer’s disease today: a two-year prospective study in 686 patients from the REAL-FR Study
10.1016/j.jalz.2007.10.018 · 2008
Real-world effectiveness, its predictors and onset of action of cholinesterase inhibitors and memantine in dementia: retrospective health record study
10.1192/bjp.2020.136 · 2021
Evaluation of clinical benefits of treatments for Alzheimer’s disease
10.1016/s2666-7568(23)00193-9 · 2023
Clinically meaningful outcomes in Alzheimer’s disease and Alzheimer’s disease related dementias trials
2025
Memantine monotherapy for Alzheimer’s disease: a systematic review and meta-analysis
10.1371/journal.pone.0123289 · 2015
Memantine MEM-MD-02 Study Group. Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment
10.1212/01.wnl.0000223333.42368.f1 · 2006
Donepezil and memantine for moderate-to-severe Alzheimer’s disease
10.1056/nejmoa1106668 · 2012
Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist—a review of preclinical data
10.1016/s0028-3908(99)00019-2 · 1999
Synaptic versus extrasynaptic NMDA receptor signalling: implications for neurodegenerative disorders
10.1038/nrn2911 · 2010
Quality of life and caregiver burden of Alzheimer’s disease among community dwelling patients in Europe: variation by disease severity and progression
10.3233/adr-210025 · 2021
Three-year trajectories of caregiver burden in Alzheimer’s disease
10.3233/jad-140360 · 2014
Reliability, validity and reference values of the Zarit Burden Interview for assessing informal caregivers of community-dwelling older persons with dementia
10.1017/s0714980800012484 · 2000
Tolerability of memantine in combination with cholinesterase inhibitors in dementia therapy
10.1097/00004850-200303000-00003 · 2003
A real-world analysis of treatment patterns for cholinesterase inhibitors and memantine among newly-diagnosed Alzheimer’s disease patients
10.1007/s40120-017-0067-7 · 2017
Real-world use of symptomatic treatments in early Alzheimer’s disease
10.3233/jad-220471 · 2023
No additional external references are available.